CONTESTED
POLITICS
Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
US President Donald Trump on Tuesday announced the final stage of his pharmaceutical tariff plan, under which imported generic medicines will continue to enter the US without duties until August 1, 2028.
Pulse Bharat · Why it matters
Read the original at Times of India ↗
The temporary reprieve for generic medicine imports ensures Indian companies can maintain their competitive edge in the US market until 2028.
Also reported by 11 other newsrooms
Economic TimesTrump 200% tariff: India’s cheap pills may still winOTVUS To Impose 200 Per Cent Tariff On Generic Drugs; India's Pharma May At RiskDeccan ChronicleUS to Impose Up to 200% Tariffs on Generic Drugs, May Impact IndiaTV9 ಕನ್ನಡಈಗ 0, ನಂತರ 100, ಬಳಿಕ 200; ಜೆನೆರಿಕ್ ಔಷಧಗಳಿಗೆ ಟ್ರಂಪ್ ಟ್ಯಾರಿಫ್ ಪ್ಲಾನ್ ಪ್ರಕಟ; ಭಾರತದ ಪ್ರಬಲ ಫಾರ್ಮಾ ಉದ್ಯಮಕ್ಕೆ ಹೊಡೆತ?TV9 ગુજરાતીBreaking News: ટ્રમ્પના 200% ટેરિફની જાહેરાતથી ભારતીય ફાર્મા શેરોમાં હલચલ, બજારમાં ભારે દબાણNDTV खबरट्रंप के 200% फार्मा टैरिफ ऐलान से सहमा भारतीय शेयर बाजार, यहां देखिए किस दवा कंपनी में आई कितनी गिरावटOdisha ReporterUpto 200% Tariffs On Generic Drugs: ଜେନେରିକ୍ ଔଷଧ ଉପରେ ୨୦୦% ପର୍ଯ୍ୟନ୍ତ ଶୁଳ୍କ ଘୋଷଣା କଲେ ଟ୍ରମ୍ପ, ଭାରତ ପ୍ରଭାବିତ ହେବାର ସମ୍ଭାବନାHindustan Times0, 100, 200: How Trump's latest generic medicines tariffs could affect IndiaTOI Business0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit IndiaNDTV · LatestTrump Announces Upto 200% Tariffs On Generic Drugs, Move May Impact IndiaLivemintAnother setback to India? Trump says US may impose tariffs upto 200% on generic drug imports. Here's why